Digital Outreach Boosts Statin Adherence in High-Risk Patients
Digital outreach significantly improves short-term statin refills among adults with established atherosclerotic cardiovascular disease or high risk and recent nonadherence, according to findings from the ADHERE-ASCVD randomized clinical trial published in JAMA on August 29, 2026. Statin nonadherence remains a primary, addressable driver of preventable cardiovascular events, prompting researchers to evaluate scalable digital communication strategies within an integrated health delivery system.
- Initial digital outreach increased 14-day statin refill rates to 14.4% compared with 12.0% for usual communication, yielding an adjusted risk ratio of 1.20.
- Among initial nonresponders, a second-stage digital outreach further increased refills to 13.0% versus 10.4% for usual communication.
- Cumulative statin refill rates through 28 days reached 24.9% for patients receiving digital outreach compared to 21.2% for those receiving standard care.
Trial Design and Patient Cohort
Led by principal investigators including Ankeet S. Bhatt and conducted via Kaiser Permanente Northern California, the ADHERE-ASCVD trial utilized a pragmatic, prospective randomized open blinded endpoint design with a sequential, multiple assignment randomized trial (SMART) structure. The study evaluated 20,604 participants with a mean age of 54.8 years, of whom 40.9% were female, 27.8% were Asian, 10.9% were Black, 33.6% were Hispanic, and 15.3% had established atherosclerotic cardiovascular disease. Eligible individuals demonstrated recent statin nonadherence and qualification for all study communication modalities.
Participants were randomized in a 1:1:1:1 ratio to receive secure portal messaging, SMS text messaging, nonsecure email, or usual communication. Initial nonresponders within a 14-day window underwent a secondary randomization to repeat the identical outreach modality, switch to a different communication channel, or receive standard care. According to trial data, switching communication modalities did not yield superior refill rates compared to repeating the same modality, with adjusted risk ratios showing no statistically significant advantage for channel-switching.
Epidemiological Context and Adherence Modifiers
Suboptimal medication persistence is a widespread barrier in clinical cardiology, where lipid-lowering therapies are essential for mitigating atherosclerotic cardiovascular disease risk. Parallel European data from retrospective cohort analyses of health administrative claims—such as those covering populations through employee health funds in the Czech Republic—indicate that proportion of days covered metrics frequently vary by age, treatment intensity, and therapeutic sequence. While older demographics often demonstrate higher baseline persistence, younger cohorts frequently require targeted behavioral interventions to bridge the gap between guideline recommendations and actual secondary prevention practices.
For patients managing complex lipid profiles or struggling with medication persistence, structured clinical oversight is critical.
Clinical Implications and Future Trajectory
Sustained research will need to determine how long these behavioral gains persist and whether repeated digital interventions translate into measurable reductions in long-term cardiovascular events.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*